Shashank Joshi/LinkedIn
Feb 2, 2026, 16:45
Shashank Joshi: Switching Among Oral Anticoagulants
Shashank Joshi, Senior Consultant at Joshi Clinic and President of Indian Academy of Diabetes, shared post on LinkedIn:
“Switching among oral anticoagulants
Switching from a DOAC to warfarin
- Apixaban
If continuous anticoagulation is needed, discontinue apixaban and start a parenteral anticoagulant with warfarin; continue the parenteral agent until the INR is therapeutic on warfarin (PI). Note that apixaban can contribute to INR elevation.
-or-
Overlap warfarin with apixaban until the INR is therapeutic on warfarin, testing right before the next apixaban dose to minimize the effect of apixaban on INR elevation (ASH). - Rivaroxaban
Discontinue rivaroxaban and start a parenteral anticoagulant with warfarin; continue the parenteral agent until the INR is therapeutic on warfarin (PI). Note that rivaroxaban can contribute to INR elevation.
-or-
Overlap warfarin with rivaroxaban until the INR is therapeutic on warfarin, testing right before the next rivaroxaban dose to minimize the effect of rivaroxaban on INR elevation (ASH).
Switching from warfarin to a DOAC
- Rivaroxaban
Stop warfarin, monitor the PT/INR, and start rivaroxaban when the INR is less than 3 (PI). - Apixaban
Stop warfarin, monitor the PT/INR, and start apixaban when the INR is less than 2 (PI).
Switching from one DOAC to a different DOAC
- Any DOAC
Start the second DOAC when the next dose of the first DOAC would have been due; do not overlap.”

Explore more posts for deeper insights into hemostasis with Hemostasis Today.
-
Nov 9, 2026, 09:29Veronica Sanchez: A Framework for Woman’s Health
-
Nov 8, 2026, 19:31Anna Kajaste-Rudnitski: Presenting AAV-Induced p53 Signalling in Human CNS Cells at ESGCT 26
-
Nov 8, 2026, 19:29David McIntosh: Cybersecurity Matters, but Blood Availability Remains the Bigger Challenge
-
Nov 8, 2026, 19:26Wenxue Ma: An Integrative Framework for Macrophage-Mediated Therapeutic Resistance in Cancer
-
Nov 8, 2026, 19:25Yildiz Yigit: Presenting a Polycythemia Vera Case at the MPN Subcommittee Session
-
Nov 8, 2026, 18:56Denis Oduor: Strengthening the Regulation and Delivery of Blood Transfusion and Transplantation Services
-
Nov 8, 2026, 18:28Raghavendra Rao: A Narrative Review on Chronic Venous Disease during Pregnancy
-
Nov 8, 2026, 17:57Dhiren Patel: PLD1-Derived Phospholipids Regulate NAD Kinase and ROS Production in Neutrophils
-
Nov 8, 2026, 17:48Andra T.: What Causes Antiphospholipid Syndrome? – Four Steps, not One Cause